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essential for protection against
pathogens but require tight control to
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Pattern-recognition receptors (PRRs) including Toll-
like receptors, RIG-I-like receptors, and cytoplasmic
DNA receptors are essential for protection against
pathogens but require tight control to avert inflam-
matory diseases. The mechanisms underlying this
strict regulation are unclear. MYSM1 was previously
described as a key component of epigenetic
signaling machinery. We found that in response to
microbial stimuli, MYSM1 accumulated in the cyto-
plasm where it interacted with and inactivated
TRAF3 and TRAF6 complexes to terminate PRR
pathways for pro-inflammatory and type I interferon
responses. Consequently, Mysm1 deficiency in
mice resulted in hyper-inflammation and enhanced
viral clearance but also susceptibility to septic
shock. We identified two motifs in MYSM1 that
were essential for innate immune suppression: the
SWIRM domain that interacted with TRAF3 and
TRAF6 and the metalloproteinase domain that
removed K63 polyubiquitins. This study identifies
MYSM1 as a key negative regulator of the innate im-
mune system that guards against an overzealous
self-destructive immune response.
INTRODUCTION
The innate immune detection and reactivity to biological threats
is mediated by pattern-recognition receptors (PRRs). PRRs
sense microbial associated molecular patterns or damage asso-
ciated molecular patterns released by unhealthy or dead cells
(Kumar et al., 2011). PRRs include the Toll-like receptors
(TLRs), which survey the extracellular and endosomal environ-
ments and the intracellular receptors such as RIG-I like receptors
(RLRs) and the newly identified cytoplasmic DNA receptors
(CDRs), which scout cytoplasmic milieu for danger signals (Ku-
mar et al., 2011). PRR triggering culminates in the induction of
pro-inflammatory cytokines and type I interferons (IFNs) that co-
ordinate antimicrobial resistance and tissue repair. However, if
unchecked, PRR activation can result in an excessive immune
response that can lead to inflammatory or autoimmune diseases.Therefore, to ensure a balanced immune response that is effec-
tive against microbes but one that is not self-injurious, PRR
signaling pathways are subject to stringent regulation.
Ubiquitin is a 76-amino-acid polypeptide present in all eukary-
otic cells (Pickart and Fushman, 2004). Ubiquitination, the cova-
lent attachment of ubiquitins to proteins by ubiquitin ligases, has
emerged as a versatile system controlling the regulation of
diverse aspects of biology including immunity (Bhoj and Chen,
2009; Harhaj and Dixit, 2012; Jiang and Chen, 2012). Ubiquitina-
tion occurs when ubiquitin ligase complexes attach single or
multiple ubiquitin molecules onto proteins, referred to as mono-
ubiquitination or polyubiquitination, respectively. During poly-
ubiquitination, multiple ubiquitins are linked onto either the
N terminus or any of the seven lysine (K) residues on ubiquitin,
leading to the formation of polyubiquitin chains of different con-
formations, which then serve as signatures for targeting proteins
to different fates (Ikeda et al., 2010; Komander and Rape, 2012;
Weissman et al., 2011). The best characterized are K48 polyubi-
quitin chains that target proteins for proteasomal degradation,
and K63 polyubiquitins that mainly control protein-protein inter-
actions during signal complex formation (Ikeda et al., 2010;
Komander and Rape, 2012; Weissman et al., 2011).
Deubiquitinases (DUBs) are proteases that specifically cleave
ubiquitin linkages thereby reversing the action of ubiquitin ligases
(Komander et al., 2009). The H2A deubiquitinase myb-like
SWIRM and MPN domains 1 (MYSM1, also known as 2A-DUB
or KIAA1915) is a metalloprotease previously reported to target
monoubiquitinated histone H2A, a mark for epigenetic transcrip-
tional repression and chromatin inaccessibility (Jiang et al., 2011;
Nandakumar et al., 2013; Nijnik et al., 2012; Wang et al., 2013;
Zhu et al., 2007). Hereweshow that beyond its role in the nucleus,
MYSM1 was a key negative regulator of innate immunity that
rapidly accumulated in the cytoplasm to inhibit proximal PRR
signaling upon microbial stimuli. We show that MYSM1 accom-
plished this through the cooperative activity of two domains:
the central SWIRMdomain and the C-terminal metalloproteinase
domain that respectively mediated the interaction with and deu-
biquitination of TRAF3 and TRAF6 signaling complexes.
RESULTS
MYSM1 Is an Essential Negative Regulator of
Pro-inflammatory and Type I IFN Responses
To identify components of the ubiquitin system involved in
the regulation of innate immunity, we screened RAW 264.7Immunity 43, 647–659, October 20, 2015 ª2015 Elsevier Inc. 647
macrophages for short hairpin RNAs (shRNAs) that affected
proinflammatory cytokine and/or type I IFN production upon
PRR activation. We observed that shRNA silencing of Mysm1
was associated with enhanced induction of the pro-inflamma-
tory cytokine genes tumor necrosis factor alpha (Tnfa) and Il1b
and the type I IFN genes Ifnb1, Ifna4, Mx1 upon stimulation
with defined agonists for different PRR pathways including
LPS (TLR4), Pam3Csk4 (TLR2) and transfected Poly (I:C)
(RLRs), or Poly (dA:dT) (RLRs, CDRs) (Figures 1A–1D). Similarly,
when infected with L. monocytogenes (L.m.), a bacterial path-
ogen that activates multiple PRRs including TLRs, RLRs, and
CDRs, or Vesicular stomatitis virus (VSV), which predominantly
activates RLRs, Mysm1 shRNA-silenced RAW 264.7 macro-
phages (Figures S1A and S1B) mounted a more robust pro-in-
flammatory and type I IFN response and were more restrictive
to VSV replication (Figure S1C).
To better characterize the function of MYSM1, we generated
Mysm1-deficient mice by crossing Mysm1 floxed mice with
K14-Cre transgenic mice, a driver line exhibiting broad active
Cre expression including oocytes (Hafner et al., 2004) leading
to the absence of MYSM1 in all cells. Mysm1/ mice had the
characteristic tail malformation described previously (Belle
et al., 2015; Gatzka et al., 2015) (Figure S2A) and showed a com-
plete lack of MYSM1 expression in the offsprings’ tissues such
as the spleen (Figure S2B). Furthermore, flow cytometric anal-
ysis of peritoneal cavities (PECs), spleen, mesenteric lymph
nodes (MLNs), and bone marrow revealed reduced lymphocyte,
natural killer, and dendritic cells counts in such mice (Figures
S2C, S2E, and S2F) as previously observed (Belle et al., 2015;
Gatzka et al., 2015; Jiang et al., 2011; Nandakumar et al.,
2013; Nijnik et al., 2012; Wang et al., 2013; Won et al., 2014).
However, no overt defects in macrophages and neutrophils
counts were noted in thesemice (Figures S2D and S2F). Accord-
ingly, in vitro differentiated bone-marrow-derived macrophage
(BMDMs) from Mysm1/ mice exhibited comparable ex-
pression of macrophage cell surface molecules F4/80 and
CD11b as those from wild-type (WT) mice (Figure 2A). Much
like the shRNA-silenced macrophages, upon infection with
L. monocytogenes or VSV, BMDMs fromMysm1/mice elicited
a higher pro-inflammatory and type I IFN response (Figures 2B–
2D) and were more resistant to VSV replication (Figure 2E).
Next we analyzed the intracellular signaling events involved
in the PRR-induction of type I IFN and pro-inflammatory re-
sponses. Mysm1/ BMDMs and Mysm1 shRNA-silenced
RAW 264.7 macrophages exhibited enhanced activation of
TANK-binding kinase 1 (TBK1), interferon regulatory factor 3
(IRF3), inhibitor of nuclear factor kappa-B kinases-a/b (IKK-
a/b), and p38 mitogen-activated protein kinase (p38 MAPK) in
response to L. monocytogenes (Figure 2F and Figure S1D),
VSV (Figure 2G and data not shown), or LPS (Figure S1E).
Consistent with activation of signaling kinases, Mysm1/
BMDMs and Mysm1 shRNA-silenced RAW 264.7 macrophages
exhibited elevated accumulation of K63-linked polyubiquitins in
response to L. monocytogenes (Figure 2F and Figure S1D),
VSV (Figure 2G), or LPS (Figure S1E).
The observed hyper-inflammatory responses in Mysm1/
cells could be due to diminished expression of negative regula-
tors of inflammatory pathways such as SOCS1 (suppressor of
cytokine signaling 1), IRAK3 (IL-1 receptor-associated kinase-3648 Immunity 43, 647–659, October 20, 2015 ª2015 Elsevier Inc.or -M), SARM1 (sterile a- and armadillo-motif-containing
protein), the ubiquitin editing protein A20 (TNFAIP3), or the deu-
biquitinase CYLD (cylindromatosis turban tumor syndrome).
However, wild-type andMysm1/ BMDMs exhibited compara-
ble levels of transcript for these regulators (Figure S3A). Further-
more, immunoprecipitation analysis did not demonstrate any
interaction between MYSM1 and negative regulators of PRR
signaling pathways such asOTUB1,OTUB2, or A20 (Figure S3B).
Together these results suggested that MYSM1 itself might be a
negative regulator of proximal PRR signaling events that control
transcriptional induction of pro-inflammatory and type I IFN
responses.
MYSM1Accumulates in Cytoplasmupon PRR Triggering
and Is Rapidly Degraded via the Proteasome
MYSM1 has thus far been described for its function in the nu-
cleus (Jiang et al., 2011; Nandakumar et al., 2013; Nijnik et al.,
2012; Won et al., 2014; Zhu et al., 2007). To investigate how
MYSM1 might control the proximal PRR signaling cascades in
the cytoplasm, we analyzed cytoplasmic and nuclear fractions
of BMDMs. Under basal conditions, MYSM1 was found to be
located entirely in the nucleus (Figure 3A). However, upon stim-
ulation with L. monocytogenes, MYSM1 accumulated rapidly in
the cytoplasm, peaked within 30–60 min and then disappeared
by 180 min post stimulation (Figure 3A). Inhibition of protein syn-
thesis using cycloheximide (CHX) abolished the accumulation of
MYSM1 in the cytoplasm but did not affect the nuclear pool of
MYSM1 (Figure 3B). Consistent with a role in negative modula-
tion of cytoplasmic PRR signaling events, the absence of
MYSM1 in the cytoplasm of CHX treated cells coincided with
elevated activation of TBK1, Ikka/b, and p38 MAPK (Figure 3B).
Next we evaluated whether the short cytoplasmic half-life of
MYSM1 was due to its degradation via the proteasome. Indeed,
inhibition of the proteasomal pathway using MG-132 resulted in
enhanced and sustained accumulation of MYSM1 in the cyto-
plasm (Figure 3C). In contrast to the CHX effect (Figure 3B),
sustained accumulation of MYSM1 in MG-132 treated cells
correlated with decreased activation of TBK1, IKKa/b, and p38
MAPK (Figure 3C). These results indicated that transient accu-
mulation ofMYSM1was due to rapid de novo synthesis and sub-
sequent proteasomal degradation. To independently test this
idea, we performed pulse-chase analysis. After 35S methionine
labeling, BMDMs were stimulated with L. monocytogenes in
the presence or absence of MG-132 and at different time points
after stimulation, cytoplasmic and nuclear fractions were har-
vested. After boiling in 1% SDS to disrupt possible non-covalent
interactions, MYSM1 was immunoprecipitated and analyzed on
SDS-PAGE for incorporated 35S methionine. Radio-labeled
MYSM1 peaked in the cytoplasm by 30 min and was undetect-
able by 180 post stimulation (Figure 3D). Consisted with protea-
somal degradation, such disappearance of freshly synthesized
MYSM1 from the cytoplasm was arrested by MG-132 (Fig-
ure 3D). In contrast, we observed no 35S methionine incorpora-
tion into the nuclear pool of MYSM1 even after more than 12 hr
of incubation with labeling medium (Figure 3D and data not
shown). This implied that in contrast to cytoplasmic MYSM1, nu-
clear MYSM1 was very stable and was not altered by de novo
synthesis or degradation during infection. In brief, these results
indicated that MYSM1 is part of a negative feedbackmechanism
Figure 1. shRNA Silencing of Mysm1 Results in Elevated Activation of Pro-inflammatory and Type I IFN Genes upon Stimulation with Ago-
nists for TLR, RLR, and CDR Pathways
(A–D) RAW 264.7 macrophages that were transduced with scrambled shRNA (Ctrl shRNA) or Mysm1 shRNA were stimulated for 3 hr with 500 mg/ml LPS (A)
100 ng/ml Pam3CSK4 (B) or transfected with 1mg/ml of Poly (I:C) (P(I:C) (C) or Poly(dA:dT) (P(dA:dT) (D) then analyzed by quantitative real time PCR (qRT-PCR) for
Tnfa, Il1b, Ifnb1, Ifna4, andMx1 transcripts. Data are shown asmean ± SEM. ***p < 0.001; (Student’s t test or one-way ANOVA followed by Bonferroni’s post-test.
Data are representative of at least two independent experiments.
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Figure 2. MYSM1Controls Innate Immunity by Inhibiting Proximal PRR Signaling Events for Pro-inflammatory and Type I IFN Gene Induction
(A) Flow cytometric analysis depicting expression of cell surface macrophage markers F4/80 and CD11b on WT and Mysm1/ mice BMDMs.
(B) WT and Mysm1/ BMDMs either uninfected or infected with L.m. for 6 hr were analyzed by qRT-PCR for Tnfa, Il1b, Ifnb1 Ifna4, andMx1 transcripts (C) WT
and Mysm1/ BMDMs either uninfected or infected with L.m. for 10 hr were analyzed by ELISA for secreted TNF-a and IL-6.
(D and E) WT andMysm1/ BMDMs either uninfected or infected with VSV for 6 hr were analyzed by qRT-PCR for Tnfa, Il1b, Ifnb1 Ifna4, andMx1 transcripts (D)
or VSV RNA (E).
(F and G) WT and Mysm1/ BMDMs either uninfected or infected with with L.m. (F) or VSV (G) for indicated time points were analyzed by immunoblotting for
p-TBK1, TBK1, p-IRF3, IRF3, p-IKKa/b, IKKa/b p-p38 MAPK, p38 MAPK, MYSM1, K63 polyubiquitin chains, and a-tubulin (loading control). Data are shown as
mean ± SEM. ***p < 0.001; (Student’s t test or one-way ANOVA followed by Bonferroni’s post-test depicts statistical significance relative to WT). Data are
representative of at least three independent experiments. Also see Figures S1, S2, and S3.
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Figure 3. MYSM1 Accumulates in Cyto-
plasm upon Microbial Stimuli and Is Rapidly
Degraded via the Proteasome
(A) Cytoplasmic and nuclear extracts of WT
BMDMs that were either uninfected or infected
with L.m. for the indicated time points were
analyzed by immunoblotting for MYSM1. Purity of
cytoplasmic and nuclear fraction is depicted by
a-tubulin and H2A loading controls.
(B) WT BMDMs either untreated or pretreated for
2 hr with 500 ng/ml Cycloheximide (CHX) were
either left uninfected or infected with L.m. for the
indicated time points and cytoplasmic and nuclear
fractions were analyzed by immunoblotting for
MYSM1, p-TBK-1, TBK-1, p-IKKa/b, p-p38
MAPK, p38 MAPK a-tubulin, and H2A.
(C) WT BMDMs either untreated or pretreated
for 1 hr with the proteasome inhibitor MG-132
(10 mg/ml) were either left uninfected or infected
with L.m. for the indicated duration and cyto-
plasmic and nuclear fractions were analyzed
by immunoblot analysis for MYSM1, p-TBK-1,
TBK-1, p-IKKa/b, p-p38 MAPK, p38 MAPK,
a-tubulin, and H2A.
(D) BMDMs labeled with 35S methionine were
either left uninfected or infected with L.m. for
indicated duration in the presence or absence of
MG-132. MYSM1 was immunoprecipitated from
denatured cytoplasmic and nuclear fractions then
analyzed for incorporation of 35S methionine on
SDS-PAGE. Corresponding whole cytoplasmic
and nuclear fractions were also analyzed by
immunoblotting for MYSM1, a-tubulin, and H2A.
Data are representative of two to three indepen-
dent experiments.that is rapidly synthesized and accumulates in the cytoplasm to
attenuate proximal PRR signaling following microbial stimuli.
Cytoplasmic MYSM1 Interacts with and Removes
K63-Linked Polyubiquitins from TRAF3 and TRAF6
Complexes
To determine the cytoplasmic interaction partners throughwhich
MYSM1 modulated proximal PRR signaling, we immunoprecip-
itated MYSM1 from cytoplasmic fractions of BMDMs infected
with L. monocytogenes. Proteomic analysis of such pull-downs
revealed a prominent presence of TRAF3 and TRAF6. Indeed im-Immunity 43, 647–659,munoprecipitations of TRAF3, TRAF6,
and MYSM1 followed by immunoblotting
for either of these proteins confirmed that
these three proteins do interact with each
other in the cytoplasm upon infection with
L. monocytogenes (Figure 4A). TRAF3
and TRAF6 are E3 ubiquitin ligases which
attach K63-linked polyubiquitin chains on
target proteins or themselves and thereby
act as signaling scaffolds for the induc-
tion of pro-inflammatory and type I IFN
responses downstream of diverse PRR
including TLRs, RLRs, and CDRs (Abe
and Barber, 2014; Bhoj and Chen, 2009;
Ha¨cker et al., 2006; Ha¨cker et al., 2011;Jiang and Chen, 2012; Oganesyan et al., 2006; Xu et al., 2005).
The interaction of MYSM1 with TRAF3 and TRAF6 (Figure 4A)
together with the enhanced accumulation of K63 polyubiquitins
observed in MYSM1 ablated cells (Figures 2F and 2G and Fig-
ures S1D and S1E) prompted us to investigate whether
MYSM1 might be involved in the removal of K63 polyubiquitins
from TRAF3 and TRAF6 signaling complexes. Indeed, immuno-
blot analysis of TRAF3 and TRAF6 immunoprecipitates revealed
an enhanced accumulation of K63- linked polyubiquitins in
TRAF6 and TRAF3 complexes fromMysm1/ BMDMs (Figures
4B and 4C) orMysm1 shRNA-silenced RAW264.7macrophagesOctober 20, 2015 ª2015 Elsevier Inc. 651
(legend on next page)
652 Immunity 43, 647–659, October 20, 2015 ª2015 Elsevier Inc.
upon infection with L. monocytogenes. (Figures S4A and S4B).
To verify whether the observed K63-linked polyubiquitin chains
were covalently attached to TRAF6 and TRAF3, we disrupted
non-covalent interactions in protein complexes by denaturing
samples at 95C in 1% SDS, after which TRAF3 and TRAF6
were immunoprecipitated and analyzed for K63 polyubiquitin
chains as well as MYSM1. Under these conditions TRAF6 and
TRAF3 from MYSM1 ablated cells exhibited elevated K63 poly-
ubiquitination (Figures 4B and 4C and Figures S4A and S4B),
indicating that MYSM1 is indeed involved in the removal of
K63 polyubiquitins from TRAF3 and TRAF6.
Because K63 polyubiquitination is essential for the recruitment
of PRR signaling molecules, we immunoprecipitated TRAF6 and
TRAF3 complexes from wild-type and Mysm1/ macrophages
in the absence of stimulation and at different time points after
stimulation with LPS or L. monocytogenes and looked for known
interaction partners. Consistent with enhanced K63 poly-
ubiquitination, Mysm1/ macrophages exhibited a more rapid
recruitment of TAB2, TAB3, NEMO, and TAK1 to the TRAF6
complex (Figures S5A and S5C and data not shown). Similarly,
Mysm1/ macrophages exhibited a faster recruitment of
TBK1 into the TRAF3 complex (Figures S5B and S5C and data
not shown). K63 polyubiquitination of TBK1 is required for
the downstream of activation of IRF3-IFN response (Wang
et al., 2012). Indeed, immunoprecipitation analysis revealed
that ablation of MYSM1 in BMDMs was associated with
enhanced K63 polyubiquitination of TBK1 upon infection with
L. monocytogenes. (Figure S5D). Together, these data sug-
gested that in response to infection, MYSM1 accumulates in
the cytoplasm where it interacts with and removes K63 polyubi-
quitin chains from TRAF6 and TRAF3 complexes, thus disrupting
the activation of downstream PRR signaling pathways for pro-in-
flammatory and type I IFN responses.
To unambiguously confirm that MYSM1 removed of K63
linked polyubiquitins from TRAF6 and TRAF3, we immunopre-
cipitated TRAF6 and TRAF3 complexes fromMysm1/BMDMs
that were uninfected or infected with L. monocytogenes and
incubated them with recombinant MYSM1 purified from bacte-
ria. Recombinant MYSM1 removed K63- but not K48-linked
polyubiquitin chains from TRAF6 and TRAF3 complexes (Figures
4D and 4E). To further test whether MYSM1 targeted K63
ubiquitin linkages in a specific manner, we incubated K63- andFigure 4. Cytoplasmic MYSM1 Interacts with and Removes K63-Linke
(A) WT BMDMs either left uninfected or infected with L.m. for 60 min were immun
downs and corresponding whole-cell lysates (WCL) were then immunoblotted fo
(B and C) Cell lysates (native) from WT and Mysm1/ BMDMs that were left un
cipitated with anti-TRAF6 (B) or anti-TRAF3 (C). Alternatively cell lysates were fi
immunoprecipitation with anti-TRAF3 or anti-TRAF6. Pull-downs from native an
TRAF3, TRAF6, and MYSM1.
(D and E)Mysm1/ BMDMs were left uninfected or infected with L.m. for 60 min
cells and incubated with recombinant MYSM1 before analysis by immunoblottin
(F) Time-course analysis of recombinant MYSM1 activity toward K63- and K4
indicated duration and visualized by silver staining.
(G) Native or denatured cytoplasmic or nuclear fractions from WT BMDMs tha
precipitated with anti-MYSM1 and pull-downs were immunoblotted for MYSM1
(T-Ub). The panel below depicts immunoblot analysis of MYSM1, TRAF3, TRA
fractions.
(H) H2A immunoprecipitates or whole-cell lystates (WCL) from WT andMysm1/
immunoblotting for indicated interaction partners. Also see Figures S4 and S5.K48-linked di-ubiquitins with recombinant MYSM1. Indeed,
MYSM1 was found to specifically cleave K63 but not K48 di-
ubiquitins (Figure 4F).
To further distinguish how MYSM1 interacted with and modu-
lated signaling components in different sub-cellular compart-
ments, we evaluated MYSM1 pull-downs from cytoplasmic
and nuclear fractions of cells that were uninfected or infected
with L. monocytogenes for the presence of ubiquitin, TRAF3,
TRAF6, and components of the epigenetic signaling machinery
such as pCAF (P300/CBP-associated factor). Cytoplasmic
MYSM1 associated with K63- and K48- linked polyubiquitins,
TRAF3 and TRAF6, but not pCAF (Figure 4G). On the other
hand, nuclear MYSM1 was constitutively associated with
pCAF and histone H2A but not TRAF3, TRAF6, or K63- or K48-
linked polyubiquitins. Denaturation effectively disrupted the
association of MYSM1 with TRAF3, TRAF6, pCAF, or K63
polyubiquitins. However, denaturation did not disrupt associ-
ated K48- linked polyubiquitins, suggesting that MYSM1
was undergoing degradative polyubiquitination in the cytoplasm
(Figure 4G).
Monoubiquitination of H2A at lysine 119 (H2A-K119) is a key
epigenetic signaling event regulated by MYSM1 (Zhu et al.,
2007). Thus, we evaluated whether MYSM1 played a role in con-
trolling the ubiquitination and interaction of H2A with epigenetic
signaling components during infection or inflammation. Immuno-
precipitation analysis revealed a comparable interaction of H2A
with pCAF inwild-type andMysm1/BMDMs that remained un-
altered in the course of L. monocytogenes infection (Figure 4H).
However, MYSM1 deficiency in these cells was associated with
elevated H2A monoubiqutination (H2A-K119 Ub). Unlike the
increased K63- linked polyubiquitination events in the cyto-
plasm, no change in H2A monoubiquitination was discernible
upon infection (Figure 4H). Together, these data show that
MYSM1 is part of distinct signaling complexes in two sub-cellular
compartments: under basal conditions MYSM1 is constitutively
associated with epigenetic signaling components in the nucleus,
but it is rapidly synthesized and accumulates in the cytoplasm
upon innate immune stimuli, where it interactswith and deubiqui-
tinates TRAF3 and TRAF6 complexes. These data also indicate
that MYSM1 undergoes K48-linked polyubiquitination and pro-
teasomal degradation in the cytoplasm, likely to prevent sus-
tained blockage in PRR signaling.d Polyubiquitin Chains from TRAF3 and TRAF6 Complexes
oprecipitated with anti-TRAF3, anti-MYSM1, anti-TRAF6, or IgG control. Pull-
r TRAF3, TRAF6, MYSM1, and a-tubulin (loading control).
infected or infected with L.m. for indicated duration were directly immunopre-
rst denatured in 1% SDS at 95C to disrupt protein-protein interaction before
d denatured samples were then immunoblotted for K63 polyubiquitin chains,
and TRAF6 (D) and TRAF3 (E) complexes were immunoprecipitated from such
g for K63- but not K48-linked polyubiquitins, TRAF6, TRAF3, and MYSM1.
8-linked diubiquitins. MYSM1 was incubated with di-ubiquitin substrates for
t were either left uninfected or infected with L.m. for 60 min were immuno-
, TRAF3, TRAF6, pCAF, K48- and K63- linked polyubiquitins or total ubiquitin
F6, pCAF, H2A, and a-tubulin in corresponding whole cytosolic and nuclear
BMDMs infected (or not) with L.m. for indicated duration were analyzed for by
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MYSM1 Interacts with and Removes K63 Polyubiquitins
from TRAF3 and TRAF6 Signaling Complexes via the
SWIRM and MPN Domains
MYSM1 contains an N-terminal SANT (Swi3, Ada2, N-Cor, and
TFIIIB) domain that mediates histone/DNA binding, a central
SWIRM (SWI3, RSC8, andMOIRA) domain presumed tomediate
interaction with chromatin associated proteins, and a C-terminal
MPN (JAB/Mov34) domain that contains the metalloprotease
activity (Zhu et al., 2007) (Figure 5A). To delineate which
MYSM1 domains were involved in the functions of MYSM1, we
used retroviruses expressing His-tagged full-length MYSM1
(MYSM1-FL) orMYSM1mutants lacking either the SANT domain
(DSANT, aa 113-164), SWIRMdomain (DSWIRM, aa 363-464), or
MPN domain (DMPN aa 563-673) to transduce Mysm1/
BMDMs. All MYSM1 forms were localized to the nucleus at
steady-state conditions but accumulated in the cytoplasm
upon L. monocytogenes infection, much like the endogenous
MYSM1 (Figure S6A). Immunoprecipitation revealed that the
SWIRM but not the SANT or MPN domain was involved in the
interaction of MYSM1 with TRAF3 and TRAF6 signaling com-
plexes upon L. monocytogenes infection (Figure 5B).
To investigate in more detail, we evaluated how deletion of the
MYSM1 domains influenced the assembly of TRAF3 and TRAF6
complexes and activation of downstream kinases. Expression of
MYSM1-FL and DSANT but not DSWIRM or DMPN mutants
attenuated total K63 polyubiquitination events and suppressed
activation of TBK1, IKKa/b, and p38 MAPK in complemented
Mysm1/ BMDMs upon L. monocytogenes infection (Fig-
ure 5C). Consistently, analysis of TRAF6 and TRAF3 immunopre-
cipitates from these cells revealed that the SWIRM and MPN
domains but not SANT domain were essential for the removal
of K63 polyubiquitins from TRAF6 or TRAF3 (Figure 5D and Fig-
ure 5E). Consequently, deletion of SWIRM and MPN domains
was associated with enhanced recruitment of signaling mole-
cules such as TAB2, TAB3, TAK1, and NEMO to the TRAF6 com-
plex (Figure 5D) or TBK1 to the TRAF3 complex (Figure 5E). To
extend these findings, we also wondered which of the domains
might be involved in the nuclear function of MYSM1. Immuno-
precipitation analysis of MYSM1 mutants from nuclear fractions
of complemented Mysm1/ BMDMs revealed that two motifs
were required for the nuclear function of MYSM1: the SANT
domain, which mediated the interaction with H2A and pCAF,
and the MPN domain, which removed monoubiquitins from
H2A-K119 (Figure 5F). Together, these findings indicate that
MYSM1 utilizes different combinations of domains to interact
with and modulate distinct signaling complexes: the SWIRM,
MPN domains for negative regulation of PRR signaling com-
plexes in the cytoplasm and SANT,MPN domains for modulation
epigenetic signaling complexes in the nucleus.
Suppression of PRR Induced Pro-inflammatory and Type
I IFN Responses by MYSM1 Requires SWIRM and MPN
Domains
To further characterize the function of theMYSM1domains in the
control of inflammation,Mysm1/ BMDMs complemented with
MYSM1 constructs were analyzed for the induction pro-inflam-
matory and type I IFNs during infection. Reiterating the impor-
tance of the SWIRM and MPN domains in suppression of PRR
signaling, MYSM1-FL, DSANT, but not DSWIRM or DMPN mu-654 Immunity 43, 647–659, October 20, 2015 ª2015 Elsevier Inc.tants significantly attenuated the enhanced induction of pro-in-
flammatory and type I IFN genes in Mysm1/ BMDMs infected
with L. monocytogenes (Figures 6A and 6B and Figure S6B) or
VSV (Figure 6C and Figure S6C). Consistently, complementation
of Mysm1/ BMDMs with MYSM1-FL or DSANT but not the
DSWIRM or DMPN rendered the cells more permissive to VSV
replication (Figure 6D). As depicted in Figure 5F, MYSM1
required the SANT domain to interact with and deubiquitinate
H2A. Therefore the ability of DSANT to suppress inflammatory
responses again illustrates that observed suppressive effects
of MYSM1 on inflammatory responses are independent of its
role in modulation of epigenetic signaling.
To further test the function of the MYSM1 domains, we over-
expressed the MYSM1 mutant constructs in MYSM1 proficient
BMDMs (Figure S6A). Under these conditions, theDMPNmutant
dramatically enhanced L. monocytogenes-induced activation of
pro-inflammatory and type I IFN genes, whereas MYSM1-FL,
DSANT, or DSWIRM mutants had no effect (Figure S6D and
data not shown). Thus by interacting with TRAF3 and TRAF6
signaling complexes via its SWIRM domain, the DMPN mutant
may interfere with the deubiquitination of these molecules by
endogenous MYSM1 and result in enhanced inflammatory re-
sponses. Together these results indicate that MYSM1 negatively
regulates PRRmediated innate immune responses via the coop-
erative activity of two domains: the SWIRM domain, which medi-
ates interaction with TRAF3 and TRAF6, and the MPN domain,
which removes the K63 polyubiquitin chains.
MYSM1 Deficient Mice Exhibit a Hyper-Inflammatory
Response, Susceptibility to Septic Shock but Enhanced
Viral Clearance
Next we investigated the physiological function of MYSM1 dur-
ing inflammation or infection. Upon intraperitoneal administra-
tion of LPS, compared to wild-type controls, Mysm1/ mice
exhibited elevated production of inflammatory cytokines in-
cluding TNF-a and IL-6, as well as induction of pro-inflammatory
and type I IFN genes (Figures 7A and S7A). Such mice displayed
more severe clinical symptoms asmeasured by weight loss (Fig-
ure 7B) and morbidity (Figure 7C). Similarly, upon infection with
L. monocytogenes, Mysm1/ mice elicited a more robust pro-
inflammatory and type I IFN gene activation in multiple organs
including the peritoneum (Figure S7B) and spleen (Figure S7C)
and exhibited more severe clinical symptoms characterized by
higher weight loss (data not shown). Similarly, when challenged
with VSV,Mysm1/micewere found tomount a higher anti-viral
response characterized by elevated transcripts for Tnfa, Il1b,
Ifnb1, Ifna4, and Mx1 in peritoneal exudates cells (PECs) and
splenocytes (Figure 7D and Figure S7D). This elevated inflamma-
tory response coincided with lower transcripts for VSV in target
organs of Mysm1/ mice (Figure 7E). Finally, to confirm the
above effects were specific toMYSM1 function inmacrophages,
we conditionally ablated MYSM1 in macrophages by breeding
Mysm1 floxed (Mysm1fl/fl) mice with LysM-Cre mice that express
Cre recombinase under the control of the myeloid cell–specific
lysozyme M promoter. Mysm1fl/fl LysM-Cre mice were devoid
of typical global Mysm1/ phenotypes including tail malforma-
tion and defects in lymphocyte pools (data not shown). However,
when challenged with VSV, Mysm1fl/fl LysM-Cre mice exhibited
a more robust pro-inflammatory and type I IFN response
Figure 5. MYSM1 Interacts with and Inactivates TRAF3 and TRAF6 Complexes via Its SWIRM and MPN Domains
(A) Schematic of His-tagged MYSM1 deletion mutants.
(B)Mysm1/ BMDMs complemented by retroviral transduction with His-taggedMYSM1-FL or the indicated deletion mutants were infected for 60 min with L.m.
Anti-His-MYSM1 immunoprecipitates or correspondingWCL from such cells were then immunoblotted for TRAF3, TRAF6, and K63 polyubiquitins, MYSM1 (His)
and a-tubulin.
(C)Mysm1/ BMDMs orMysm1/ BMDMs complemented with MYSM-FL or DSWIRM, DMPNmutants were either left uninfected or infected with L.m. for 15,
30, or 60 min, and WCL were analyzed by immunoblotting for p-TBK-1, TBK-1, p-IKKa/b and IKKa/b, TRAF6, TRAF3, TAB2, TAB3 NEMO, and TAK1. Alter-
natively, TRAF6 (D) and TRAF3 (E) complexes from WCL from (C) were isolated by immunoprecipitation and analyzed for the K63 polyubiquitins or the indicated
interaction partners.
(F) ControlMysm1/ BMDMs orMysm1/ BMDMs complemented with MYSM-FL, DSANT, DSWIRM, or DMPNmutants were either left uninfected or infected
with L.m. for 15, 30, or 60 min. MYSM1 complexes from nuclear fractions were then isolated by immunoprecipitation and analyzed along with corresponding
nuclear fractions for H2A monoubiquitination (H2A [K119 Ub]) or the indicated interaction partners.
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Figure 6. MYSM1 Suppress Innate Immune Response via the SWIRM and MPN Domains
(A)Mysm1/BMDMs orMysm1/BMDMs complementedwithMYSM-FL orDSWIRM,DSANT,DMPNmutants were either left uninfected or infectedwith L.m.
for 10 hr and then analyzed for secreted TNF-a and IL-6 by ELISA.
(B and C) Alternatively, BMDMs were infected for 6 hr with L.m. (B) or VSV (C) and analyzed by qRT-PCR for Tnfa and Ifnb1 transcripts.
(D) Corresponding qRT-PCR analysis of VSV RNA in samples depicted in (C). Data are representative of two independent experiments and are shown as mean ±
SEM. ***p < 0.001; (Student’s t test or one-way ANOVA followed by Bonferroni’s post-test depicts statistical significance relative to MYSM-FL). Also see
Figure S6.(Figure 7F) and a showed faster viral clearance (Figure 7G) as
compared to Mysm1fl/fl mice. Together, these data show that
MYSM1 is an important negative regulator of innate immunity
and that its absence culminates in an exaggerated inflammatory
response that enables a faster viral clearance but renders the
host more susceptible to immunopathology of inflammatory dis-
eases such as sepsis.
DISCUSSION
Infection by most microbes often leads to the simultaneous or
sequential activation of multiple PRR pathways. Therefore, to
avert a disproportionate self-destructive immune response, it is
essential that once activated, all these pathways be attenuated
in a synchronized fashion. A number of enzymes including A20
(Boone et al., 2004; Shembade et al., 2010; Turer et al., 2008),
CYLD (Yoshida et al., 2005), USP4 (Zhou et al., 2012), USP25
(Zhong et al., 2013), OTUB1/2 (Li et al., 2010), and DUBA (Kaya-
gaki et al., 2007) have been implicated in the dampening of
innate immune responses. However, there is a growing appreci-
ation that these enzymes alone cannot account for the tight regu-
lation of all the PRRs pathways and that their mechanisms are
not well defined. Of these enzymes, the ubiquitin editing enzyme656 Immunity 43, 647–659, October 20, 2015 ª2015 Elsevier Inc.A20 and the deubiquitinase CYLD are among the most exten-
sively studied. However, increasing evidence suggests that
A20 preferentially targets the pro-inflammatory responses
(Boone et al., 2004) and that many of the negative regulatory
function of A20 are independent of its deubiquitinase activity
(De et al., 2014; Shembade et al., 2010). On the other hand,
whereas CYLD was previously reported to inhibit TLR and RLR
pathways (Friedman et al., 2008; Yoshida et al., 2005; Zhang
et al., 2008), recently CYLD has been shown to be vital for effec-
tive anti-viral innate immunity (Zhang et al., 2011) thus casting
doubt about the net function and exact mechanisms of CYLD
in antimicrobial innate immunity. Therefore, how different PRR
pathways for both pro-inflammatory and type I IFN responses
are terminated in a coordinated and timely manner during infec-
tion or inflammatory situations remains unclear.
K63-linked polyubiquitination of TRAF6 and TRAF3 is vital for
the induction of pro-inflammatory and type I IFN responses
downstream of TLRs, RLRs, and CDRs (Abe and Barber, 2014;
Bhoj and Chen, 2009; Ha¨cker et al., 2006; Ha¨cker et al.,
2011; Jiang and Chen, 2012; Oganesyan et al., 2006; Xu et al.,
2005). MYSM1 is a member of the JAMM family of metalloen-
zymes that cleave ubiquitins in a linkage-specific manner
(Komander et al., 2009). Previously, MYSM1 was described as
Figure 7. MYSM1 Deficient Mice Elicit Hyper-inflammatory Responses, Are More Susceptible to Septic Shock but Resistant to Viral
Replication
(A) WT (n = 5) andMysm1/mice (n = 5) were inoculated via intraperitoneal (i.p.) route with carrier buffer (Ctrl) or LPS (20mg/kg). 6 hr later, sera were analyzed by
for TNF-a and IL-6 (B and C) Alternatively, WT (n = 14) andMysm1/ (n = 14) mice were challenged via i.p. with of LPS (20 mg/kg) then monitored for weight loss
(B) and morbidity (C).
(D and E) WT (n = 5) andMysm1/mice (n = 5) were inoculated i.p. with carrier buffer (Ctrl) or 23 107 pfu VSV and 6 hr later peritoneal cells (PECs) were analyzed
by qRT-PCR for Tnfa, Il1b, Ifnb1, Ifna4, and Mx1 transcripts.
(E) qRT-PCR quantification of VSV RNA in PECs and spleens of mice depicted in (D).
(F) qRT-PCR analysis of transcripts for Tnfa, Il1b, Ifnb1, Ifna4, andMx1 genes in PECs ofMysm1fl/fl (n = 5) orMysm1fl/flLysM-Cre (n = 5) mice 6 hr after inoculation
of 2 3 107 pfu VSV via i.p. (E) qRT-PCR quantification of VSV RNA in PECs and spleens of mice depicted in (F).
(A–E) and (F and G) represent 4 and 2 independent experiments, respectively. Data are shown as mean ± SEM. ***p < 0.001; (Student’s t test or one-way ANOVA
followed by Bonferroni’s post-test depicts statistical significance to Ctrl). Also see Figure S7.a deubiquitinase that specifically removes monoubiquitins from
H2A (Zhu et al., 2007) and hence has been associated with the
control of diverse epigenetic signaling processes (Jiang et al.,
2011; Nandakumar et al., 2013; Nijnik et al., 2012; Wang et al.,
2013; Won et al., 2014; Zhu et al., 2007). Whether MYSM1 is
involved in signaling events outside the nucleus was not clear.
Here we demonstrate that in response to diverse innate immune
stimuli, MYSM1 accumulated in the cytoplasm where it inter-
acted with and specifically removed K63 polyubiquitin chains
from TRAF3 and TRAF6 complexes thereby terminating proximal
TLR, RLR, and CDR signaling processes for pro-inflammatory
and type I IFN gene induction. Thus, beyond its function in the
nucleus, the ability to target these cytoplasmic molecules, pla-ces MYSM1 at crucial junctures in PRR signaling enabling it to
act as a ‘‘rheostat’’ for innate immune regulation. We show that
in order to distinctly control these processes at different sub-
cellular compartments, MYSM1 employed different combination
of motifs: the SANT, MPN motifs to modulate epigenetic
signaling complexes in the nucleus and the SWIRM, MPN do-
mains to interact with and inhibit PRR signaling complexes in
the cytoplasm.
Our data also indicate that the localization and function of
MYSM1 in the nucleus and cytoplasm was subject to strict
spatiotemporal regulation.Whereas nuclear MYSM1was consti-
tutively resident in the nucleus where it has a housekeeping func-
tion in histone H2A modification, cytoplasmic MYSM1 wasImmunity 43, 647–659, October 20, 2015 ª2015 Elsevier Inc. 657
temporally regulated. The short cytoplasmic half-life of MYSM1
that was carefully balanced by rapid de novo synthesis and
subsequent degradation might be essential to avert prolonged
suppression of inflammatory pathways that might otherwise be
deleterious to the host. Thus, the ability of MYSM1 to promptly
amass in the cytoplasm, inhibit proximal PRR signaling events,
and then undergo proteasomal degradation highlights the role
of MYSM1 as part of highly versatile negative feedback regula-
tory mechanism which, in response to biological danger, is
swiftly activated in an ‘‘on-and-off’’ manner so as to restore im-
mune homeostasis. This study highlights MYSM1 as a potential




Animal experiments were approved and carried out according to the guide-
lines set out by the Regional Animal Ethic Committee approval no. A107-11
or A53-14. For germline deletion of Mysm1, male Mysm1 floxed mice
(Mysm1_A04; Mysm1tm1a(DMP)Wtsi MGI#: 2444584 from KOMP Repository at
UC Davis) were bred with female transgenic K14-Cre mice (Hafner et al.,
2004). K14-Cre is expressed in maternal oocytes and remains active until after
fertilization, hence the ability to mediate germ-line deletion of floxed alleles in
offsprings of female K14-Cre mice (Hafner et al., 2004). K14-Crewt/tg
Mysm1flox/flox offsprings were further crossed with each other to generate
Mysm1/ mice without Cre allele. For myeloid specific ablation of Mysm1,
Mysm1flox/flox were bred with LysM-Cre transgenic mice to generateMysm1fl/fl
LysM-Cre. Breeding of mice was done at the Umea˚ Transgene Facility (UTCF),
whereas in vivo infection experiments were performed in Umea˚ Center for
Comparative Biology (UCCB). Animals were infected via intraperitoneal (IP)
route with 23 107 pfu of VSV dose after which organs were harvested 6 hr later
and analyzed for viral replication inflammatory gene expression. For LPS
induced septic shock, mice were challenged with LPS (20 mg/kg) via intraper-
itoneal route and analyzed 6 hr later for cytokine levels in peritoneal exudates
or serum. For L. monocytogenes experiments, mice were inoculated via intra-
peritoneal route with 1 3 105 cfu. Mice were monitored further for clinical
symptoms and mice exhibiting high morbidity i.e., with a combination of
hunchback posture, lethargy, loose fecal pellet, ruffled fur, >25% weight
loss, and difficulty in breathing and movement were euthanized. 8- to 14-
week-old mice were used.
Immunoprecipitation and Immunoblot Analyses
Cells were lysed in 2X Laemmli buffer then analyzed directly by SDS-PAGE,
immunoblotting. For immunoprecipitation, cells were suspended in lysis buffer
(1% NP-40, 50 mM Tris-HCl, 150 mM NaCl pH 7.5, 1 mM NaF, 2 mM PMSF,
protease inhibitor cocktail [Roche Applied Science], 1 mM sodium orthovana-
date and 10 mM sodium pyrophosphate). For denaturation, lysates were sus-
pended in 100 ml TSD buffer (50mM, Tris pH 7.5, 1%SDS, and 5mMDTT) then
boiled (10min). After centrifugation (13,000 rpm for 5min at room temperature)
to clear the lysates, samples were diluted in 1.2 ml of TNN buffer (50 mM Tris
pH 7.5, 250 mMNacl, 5 mM EDTA, and 0.5% NP40). Samples were incubated
with specific antibodies at 4 overnight with rotation and the complex were
pulled down by Protein A/G agarose bead. Agarose beads were then washed
three times with protein lysis buffer containing the standard salt concentra-
tions, suspended in Laemmli buffer and analyzed by SDS-PAGE immunoblot-
ting. For ubiquitination assays, cells were lysed with ubiquitination lysis buffer
(8 M urea, 50 mM Tris [pH 7.5], 25 mM NaCl, protease cocktail inhibitors,
5 mM EDTA, 2 mM N-ethylamide). After sonication, lysates were centrifuged
(14,000 rpm for 2 min) to remove precipitates. Samples were diluted in
reducing SDS sample buffer then boiled at 70C for 10 min before by SDS-
PAGE and immunoblotting with anti-ubiquitin antibodies.
Expression and Purification of Recombinant MYSM1
Mouse MYSM1 gene with C-terminal His tag (His-MYSM1) was synthesized,
then cloned into the pET30a expression plasmid, and subsequently trans-658 Immunity 43, 647–659, October 20, 2015 ª2015 Elsevier Inc.formed into E. coli. Strain BL21 (DE3). E. coli BL21 (DE3) harboring target
pET30a-His MYSM1 was cultured in 1 L M9 medium and induced with
1 mM IPTG at 15C overnight. Cell pellets were lysed by sonication in the
buffer 50mMTris-HCl, pH 8.0 with PMSF. The supernatant after centrifugation
was purified by Nickel column. His-MYSM1 was eluted with a stepwise
gradient of imidazole and fractions were analyzed by SDS-PAGE and
immunoblotting.
In Vitro Deubiqutinase Assays
Mysm1/ BMDMs infected with (or not) L. monocytogenes for 60 min were
lysed in NP-40 lysis buffer as described before. Lysates were then immuno-
precipitated using anti-TRAF3 and anti- TRAF6 antibody, incubated o/n at
4C with gentle shaking. Thereafter 50 ml of Protein A/G agarose was added
and incubated for another 4 hr with gentle shaking. Immunoprecipitates were
then washed five times with NP-40 lysis buffer. For in vitro deubiquitination
assay, beads were resuspended in 13 DUB buffer (125 mM HEPES,
pH 7.5, 25 mM MgCl2, 10 mM NaF, 10 nM okadaic acid, 500 mM NaCl,
2.5 mM DTT, 0.5 mg/ml BSA). 10 ml of recombinant His-MYSM1 (1mg) was
then added to the bead slurry followed by incubation for 30 min at 37C
with gentle shaking. The reaction was then stopped by adding 2X SDS
loading buffer followed by western blot analysis with anti K63 and K48 ubiq-
uitin antibody.
In vitro ubiquitin linkage specificity assay were performed as previously
described (Licchesi et al., 2012). Briefly, 23 DUB assay buffer (150 mM
NaCl, 25 mM Tris, pH 7.5, and 10 mM DTT) and activated at 23C for
10 min. 10 ml of 23 concentrated DUB were mixed with 1–2 mg diubiquitin
and 2 ml of 103 DUB Buffer as described above in 20 ml of reaction mixture.
Recombinant His-MYSM1 was diluted to 50:50 in 150 mM, NaCl, 25 mM
Tris, pH 7.5, and 10 mM DTT and activated at 23C for 10 min. Subsequently,
10 ml of diluted enzymewasmixed with 1–2 mg of K63 and K48 diubiquitins and
2 ml of 103DUB buffer (500mMNaCl, 500mMTris, pH 7.4, and 50mMDTT) in
20 ml of reaction mixture. At different time points (5 and 30 min) the enzymatic
reactions were stopped by addition of 4 ml SDS sample buffer containing
100 mM DTT. 5 ml aliquots were then resolved on 4%–12% SDS-PAGE
gradient gel run in MES buffer (Life Technology). Ubiquitin cleavage was de-
tected by silver staining using the Sliver Stain Plus kit (BioRad).
Pulse-Chase Assay
BMDMs were incubated for 30 min in pulse medium (DMEM methionine/
cysteine-free, 2 mM L-glutamine, 15% dialyzed FBS, 100 U/ml penicillin,
100 mg/ml streptomycin with 70mCi/ml) [35S] methionine. Thereafter cells
were infected with L. monocytogenes (MOI 20). Cells were then washed with
PBS, replaced with chase medium (starving medium containing 15 mg/ml
L-methionine and L- cysteine) and incubated further in the presence and
absence of MG132. At different time points (10, 20, 30, 60, 90, 120,
180 min), cells were harvested and cytoplasmic and nuclear fraction were
immunoprecipited with anti- MYSM1 antibody and visualized with autoradio-
graphic films.
Statistical Analysis
All data are shown as mean ± SEM. Statistical analysis was performed using
a two-tailed Student’s t test or ANOVA test followed by Bonferroni’s
post hoc test. Generation of Kaplan-Meier survival curve and analysis of
statistical significance for mouse survival study performed in Graph pad
Prism 5.0.
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